AstraZeneca is trying to invoke the Orphan Drug Act to protect its blockbuster, on the grounds it is approved to treat a rare pediatric condition.
Updates with report of FDA approval for generic competitor.
AstraZeneca won’t be able to keeps generic versions of Crestor off the market while it sues to shield its blockbuster cholesterol drug from competition, a federal judge has ruled. Almost immediately, a new competitor announced it had received FDA approval for a generic version of rosuvastatin calcium tablets.
US District Judge Randolph Moss ruled late Tuesday that the drug maker was not likely to win a lawsuit seeking another 7 years of protection for Crestor, and thus denied AstraZeneca’s request for a temporary restraining order. The ruling opens Crestor to broader competition, barring an appeal.
By midday Wednesday, Sun Pharma announced that once of its subsidiaries had received final approval from FDA for rosuvastatin calcium. John Rother of the Campaign for Sustainble Rx Pricing praised the news as a win for consumers.
“We are glad to see that the court rejected AstraZeneca’s effort to abuse the Orphan Drug Act and restrict generic competitors to Crestor,” Rother said in a statement. “Additional competition in the prescription drug market—including generic options—is crucial to lowering prescription drug prices and providing patients with more affordable choices.”
Crestor lost patent protection July 8, 2016, but AstraZeneca had pre-emptively sued FDA to block rivals. AztraZeneca sought to invoke the Orphan Drug Act to thwart generics, on the grounds that only Crestor had approval to treat a rare pediatric condition that elevates cholesterol. That move was loudly opposed by consumer advocates and members of Congress.
US Senator Bernie Sanders of Vermont wrote FDA a letter July 7, 2016, saying AstraZeneca was trying to use a “loophole” to protect its blockbuster at the expense of consumers.
Attorney Chad Landmon, on behalf of generic drug maker Par Pharmaceuticals, had argued in a filing that AstraZeneca’s actions flew in the face of a recent ruling involving Otsuka and its antipsychotic, Abilify. Last year, Otsuka sought to block competitors on the grounds that Abilify had been approved to treat a rare disease, but a different judge ruled against the drug maker.
“AstraZeneca now seeks extraordinary relief,” Landmon said, including an order to bar generic competitors until May 27, 2023, “despite the fact that another court has already endorsed FDA’s ability to permit a (generic) applicant to carve out pediatric labeling protected by orphan drug exclusivity under nearly identical facts.”
An AstraZeneca spokeswoman told Bloomberg that the company was “disappointed” and would evaluate its options.
Generics that reach the market will also compete with Allergan’s Watson Pharmaceuticals, which gained the right to sell its version through a settlement with AstraZeneca. That drug reached the market in early May. If other generic competitors reach the market, Crestor sales are expected to fall significantly from the $5 billion generated worldwide last year.
According to the American Heart Association, 98.9 million people over age 20 have elevated levels of total cholesterol.
Research Points to Potential MCIDs in Diabetes Distress Scale–17
November 29th 2023Researchers identified a value of at least 0.25 to be a minimal clinically important difference (MCID) in diabetes distress, and MCID values of 0.38 and 0.39 for emotional and interpersonal distress subscales and physician and regimen distress subscales, respectively.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More